Company ProfilePremium

Cheilbio Co., Ltd.

Company Profile Analysis

Ticker: 052670.KQ주식회사 제일바이오

ESOMAR 23 Corporate BadgeISO Certifications Badge
Cheilbio Co., Ltd. - Company showcase

Year Founded & Workforce

1977

42 Employees

Cheilbio Co., Ltd. logo

Cheilbio Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cheilbio Co., Ltd. Overview

Cheilbio is a small, founder-built Korean manufacturer of veterinary medicines and feed additives, established in 1977 by a Seoul National University veterinary graduate and incorporated in 1989. Its portfolio spans functional feed additives, therapeutic drugs (antibiotics, antimicrobials, parasiticides, disinfectants), fermentation-based products (probiotics, enzymes, yeast culture) and diagnostic kits for cattle, pigs, poultry, aquaculture and pets. Revenue peaked near KRW 39.5bn in FY2014 and has since contracted to KRW 14.4bn in FY2025, with operating losses every year from FY2020 to FY2025. Since 2023 the company has been defined less by its products than by a family control dispute between the founder and his eldest daughter, criminal complaints (all later closed without indictment), two consecutive audit-opinion disclaimers, and a KRX delisting in February 2026 that a court has since ruled void at first instance. The business retains a cash-heavy, low-liability balance sheet, which is the core of its residual value case.


Company's own description

The FY2024 business report (filed with KIND on 7 April 2025) describes Cheilbio as a company established in January 1977 whose principal business is the manufacture of veterinary medicines and feed additives. The report classifies all activity under a single business segment, "animal drug manufacturing" (동물약품제조업). FnGuide's company summary, drawn from company filings, characterises the business as research, development, manufacturing and sale of fermentation-based animal drugs, alongside commercialisation of R&D results in product formulation and general feed additives.

Morningstar's profile lists the offering set as antibiotics, antimicrobials, lactobacillus (probiotic) products, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, diagnostic kits (ELISA test kits, virus test kits and DNA kits) and feed additives, used for cattle, pigs, chickens, pets and other animals. Simply Wall St groups the range into nutrients/immune products, probiotics, functional products, antibiotics/antibacterials, anthelmintics/anticoccidials, kits, and disinfectants, serving poultry, swine, cattle, fisheries and pets.

Independent characterisation

Cheilbio is best understood as a sub-scale, domestically focused, mid-value-chain formulator and manufacturer. It converts purchased active ingredients and raw materials (the factory registry lists vitamins and antibiotics as principal raw materials) into finished veterinary drugs and feed additives at its Ansan plant, and it also manufactures fermentation-derived ingredients from in-house technology dating to 1990. It does not appear to own proprietary new chemical entities; the one product line described in detail in the FY2024 filing, a florfenicol injectable, competes head-to-head with a rival using the same originator-sourced raw material.

Business model and revenue model. Revenue is almost entirely product sales (manufactured products plus some traded merchandise). There is no disclosed service, subscription or licensing revenue. The FY2024 filing splits sales by channel as follows: feed-mill and special sales (50.10%), field sales to farms, veterinarians and distributors (34.25%), and exports (15.65%).

Value chain position. Upstream: purchases APIs (e.g., florfenicol of Novartis origin is implied by the filing's competitive note), vitamins and other inputs. Midstream: formulation, fermentation, and packaging at a KVGMP-type animal drug plant. Downstream: sells to (i) feed manufacturers who incorporate additives into compound feed, (ii) field channels (veterinary distributors and producers), and (iii) overseas distributors.

Customer types. Feed mills and integrators; livestock and poultry farms; veterinary distributors/clinics; aquaculture; companion-animal channels; export distributors.

End-markets. Korean livestock production (swine, poultry, cattle), aquaculture, and companion animals; selected export markets. A 2015 profile (Etoday) cited exports to 18 countries including China, Indonesia, Vietnam, Japan, Thailand and Taiwan; the current country list is not publicly disclosed.

Revenue mix by nature (FY2024, derived from KIND excerpt): manufactured products KRW 10,395.1M (74.7%); merchandise and other KRW 3,512.7M (25.3%, derived as the residual to total revenue).

Strategy

Stated corporate strategy. No investor-day material, medium-term plan or strategy statement was found in recent filings or press. The most recent articulated growth strategy dates from 2015 (CEO Sim Seung-gyu): leverage core fermentation and antibiotic-alternative technology, enter China through a local subsidiary, and reach KRW 100bn revenue by 2020. That target was missed by a wide margin (FY2021 revenue was about KRW 16.9bn).

Sustainability/ESG commitments, cost programmes and financial targets: not publicly disclosed. Management guidance: none published.

Products & Services

Cheilbio does not publish a product catalogue with specifications in sources accessible to this research. Pricing, launch years and specifications are not publicly disclosed for any product. The catalog below lists every product or category named in public sources.

Assessment. The portfolio is broad for a company of this size, covering nutrition, treatment, prevention and diagnosis, which suggests a distributor-friendly "full basket" model rather than a few differentiated products. Only one product (Flormax) is described in the FY2024 filing in any detail, and that description itself highlights direct competition with an equivalent product. Flagship-product data, version history and pricing are not publicly disclosed.

Product Portfolio

Category / productDescription (as disclosed)Target species / customerNotesSource

Flormax (플로르맥스) injection

Florfenicol-based injectable specialising in treatment of pleuropneumonia; positioned as a respiratory-disease therapeutic

Swine (pleuropneumonia indication); field channel

Filing names Woojin (Woogene B&G) as main competitor, also using Novartis-origin raw material

KIND FY2024 report

Saccharoculture (사카로컬춰)

Flagship fermentation product launched on the back of the company's 1990 domestic fermentation-raw-material technology

Livestock feed

Launch year not specified (post-1990)

Etoday (2015)

Functional additives

Feed additives incl. nutrients/immune products, organic trace minerals, enzyme preparations

Feed mills; poultry, swine, cattle, aquaculture

Largest product line in FY2022 and FY2024

KIND; Morningstar; Simply Wall St

Therapeutics and other

Antibiotics, antimicrobials, anthelmintics, anticoccidials, disinfectants/antiseptics

Farms, vets, distributors

30.8% of FY2024 revenue

KIND; Morningstar

Fermentation products

Lactobacillus/probiotic products, enzyme preparations, yeast-culture type products

Feed and field

Described as antibiotic-alternative technology in 2015 profile

KIND; Etoday; aboda.kr summary

Vaccines

Listed in Morningstar profile

Livestock

Not broken out in revenue table; may sit in merchandise/other

Morningstar

Diagnostic kits

ELISA test kits, virus test kits, DNA kits

Vets, farms, labs

KRW 129.8M revenue FY2024

KIND; Morningstar

Health functional food / food additives

Listed as corporate purposes in articles of incorporation of some industry peers; not confirmed for Cheilbio

—

Not publicly disclosed for Cheilbio

—

Financial Narrative

Basis and sources. FY2022-FY2024: KIND FY2024 business report excerpt (FY2023 restated). FY2025: JobKorea/KODATA record of FY2025 financial statements (business report filed 23 March 2026). FY2021: FnGuide (values reported in KRW 100M units, converted; therefore rounded to the nearest KRW 100M). EBITDA FY2021-FY2024: FnGuide. Blank cells = not publicly disclosed. The FY2025 audit opinion was not found; FY2023 and FY2024 statements received audit disclaimers, so all figures should be read with that qualification.

Income statement

FY2025 cost of sales and SG&A are derived (revenue minus gross profit; gross profit minus operating income). FY2024 EPS from FnGuide. Diluted EPS not publicly disclosed. No dividend declarations were found for FY2021-FY2025.

Below-the-line detail. FY2024: other gains KRW 470.6M, other losses KRW 308.6M, finance income KRW 508.9M, finance costs KRW 20.5M. FY2022: finance income KRW 1,106.4M, finance costs KRW 1,563.5M (the high finance cost likely reflects investment valuation losses; not specified). FY2025: non-operating income KRW 722.4M, non-operating expense KRW 278.8M.

Margins and growth (%)

All derived from 6.1. Revenue CAGR FY2021-FY2025: -3.8% (derived). FY2022-FY2025: -2.0% (derived). Long-run: from the FY2014 peak of KRW 39.53bn to FY2025's KRW 14.45bn, revenue has fallen 63% (derived), a CAGR of about -8.7% over 11 years.

Commentary. Three phases are visible. (1) FY2021-FY2022: revenue near KRW 15-17bn with thin gross margins (15.9% in FY2022) and operating losses of KRW 1.5-1.7bn, indicating that a low-margin, feed-mill-heavy mix could not cover a fixed SG&A base of about KRW 4bn. (2) FY2023: the dispute year. Revenue fell 36% (restated), mainly through the collapse of functional additives, while SG&A rose to KRW 4.35bn (likely including legal and governance costs; not itemised), producing the worst operating margin of the period (-20.5%). (3) FY2024-FY2025: partial recovery. Revenue rebounded to KRW 13.9-14.4bn, gross margin held at about 23%, and operating losses narrowed to KRW 1.06bn and then KRW 0.67bn. Net losses were much smaller than operating losses in FY2024-FY2025 because of non-operating and financial income (consistent with a large cash balance earning interest). The inflection is real but incomplete: the company remains loss-making at the operating line on an SG&A base it has not materially reduced.

Balance sheet

FY2024 figures from DigitalToday (Feb 2026), citing FY2024 statements.

Additional balance-sheet evidence. In the delisting-nullity case, counsel (Dongin LLC) told the court that Cheilbio held KRW 16.1bn of cash-equivalent assets within total assets of KRW 32.9bn (Hankyung, April 2026); the balance-sheet date was not specified in reporting but is most likely 31 December 2025. JobKorea/KODATA separately reports FY2025 total-asset growth of -5.53%, which would imply about KRW 33.3bn (derived) on the FY2024 base; the small gap to KRW 32.9bn is unexplained. Financial debt is not publicly disclosed; with total liabilities of only KRW 3.9bn at FY2024, any borrowings are necessarily small. Net debt is therefore negative (net cash), likely in the order of KRW 12-16bn, but the exact figure is not publicly disclosed. Capital reduction completed in October 2025 and conversion to no-par shares changed the composition of equity (share capital vs. reserves) but not total equity; details are not publicly disclosed.

Cash flow

Cash-flow statements were not accessible in sources reviewed. Known capital-return events: a KRW 2.5bn treasury trust in 2017; a treasury-share disposal decision on 12 June 2025 (amount not disclosed); and a buyback authorisation of up to 1,940 post-consolidation shares (KRW 2,022.8M ceiling) for 9-20 February 2026, with an acquisition-result report filed 25 February 2026 (amount executed not disclosed). Treasury holdings stood at 970 shares (5.00%) on 13 February 2026 (FnGuide).

Ratios

Sources: ROE FY2024 FnGuide; ROE and ROIC FY2025 JobKorea/KODATA; ROA FY2024, liabilities/equity and asset turnover derived from DigitalToday FY2024 figures; P/B from FnGuide (FY2024 reflects the suspended price of KRW 2,080). Current ratio, debt/equity on financial debt, net debt/EBITDA, interest coverage and cash conversion cycle: not publicly disclosed. Interest coverage is not meaningful given negative operating income (FY2024 finance cost was only KRW 20.5M).

Ratio commentary. Returns are marginally negative and improving (ROE -1.33% to -0.78%). The balance sheet is conservatively financed; the problem is not solvency but earnings power and asset productivity, with each KRW of assets generating only KRW 0.40 of sales in FY2024 because nearly half of assets are cash.

Interim results 2026

The Q1 2026 report (filed 15 May 2026) and H1 2026 report (filed 14 August 2026) exist (Saramin/NICE disclosure list), but their figures were not found in public sources reviewed: not publicly disclosed in accessible sources. For reference, FnGuide's last available interim data (nine months to September 2025) show revenue of KRW 10.6bn and a net loss of about KRW 0.2bn.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Product Lines

Product line (KRW Mn)FY2022FY2023FY2024FY2025

Functional additives (KRW Mn)

4,509.11,076.73,868.6—

Therapeutics and other (KRW Mn)

3,845.65,290.44,284.8—

Fermentation products (KRW Mn)

2,360.22,190.02,111.9—

Diagnostic kits (KRW Mn)

127.1167.2129.8—

Manufactured products subtotal (KRW Mn, derived)

10,842.08,724.310,395.1—

Merchandise and other (KRW Mn, derived residual)

4,506.61,098.53,512.7—

Total revenue (KRW Mn)

15,348.69,822.913,907.814,447.4

Product line share of total revenue (%)

Product line share of total revenue (%)FY2022FY2023FY2024

Functional additives (%)

29.411.027.8

Therapeutics and other (%)

25.153.930.8

Fermentation products (%)

15.422.315.2

Diagnostic kits (%)

0.81.70.9

Merchandise and other (%)

29.411.225.3

Product line YoY growth (%)

Product line YoY growth (%)FY2023FY2024

Functional additives (%)

-76.1259.3

Therapeutics and other (%)

37.6-19.0

Fermentation products (%)

-7.2-3.6

Diagnostic kits (%)

31.5-22.4

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Mn)

16,90015,348.69,822.913,907.814,447.4

Revenue as originally reported (KRW Mn)

16,90015,348.612,110.813,907.814,447.4

Cost of sales (KRW Mn)

—12,904.07,493.810,689.111,091.5

Gross profit (KRW Mn)

—2,444.62,329.13,218.73,355.9

SG&A expenses (KRW Mn)

—3,930.14,347.04,280.44,021.2

Operating income (KRW Mn)

-1,700-1,485.5-2,017.9-1,061.7-665.3

EBITDA (KRW Mn)

-1,400-1,200-1,800-900—

Pre-tax income (KRW Mn)

—-1,755.6-1,464.1-411.4-221.7

Income tax expense (KRW Mn)

—-47.8-18.35.29.4

Net income (KRW Mn)

-700-1,707.8-1,445.8-416.6-231.2

EPS basic (KRW, pre-consolidation)

———-14—

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

—-9.2-36.041.63.9

Gross margin (%)

—15.923.723.123.2

Operating margin (%)

-10.1-9.7-20.5-7.6-4.6

EBITDA margin (%)

-8.3-7.8-18.3-6.5—

Pre-tax margin (%)

—-11.4-14.9-3.0-1.5

Net margin (%)

-4.1-11.1-14.7-3.0-1.6

Balance Sheet

MetricFY2024

Total assets (KRW Mn)

35,200

Total liabilities (KRW Mn)

3,900

Total equity (KRW Mn)

31,300

Returns & Leverage Ratios (%) and Valuation Multiples (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

———-1.33-0.78

ROA (%)

———-1.18—

ROIC (%)

————-0.67

Total liabilities to equity (%)

———12.5—

Asset turnover (x)

———0.40—

Price to book high (x)

3.122.361.841.62—

Price to book low (x)

2.190.910.891.62—

Revenue by Region and Revenue by Region (%)

Channel / region (KRW Mn)FY2022FY2023FY2024FY2025

Export (KRW Mn)

——2,177.0—

Domestic feed and special sales (KRW Mn)

——6,967.3—

Domestic field sales (KRW Mn)

——4,763.5—

Total (KRW Mn)

15,348.69,822.913,907.814,447.4

Channel share (%)

FY2024

———

Export (%)

15.65———

Domestic feed and special sales (%)

50.10———

Domestic field sales (%)

34.25———

Share Price and Market Valuation

MetricFY2021FY2022FY2023FY2024FY2025

Share price high (KRW)

4,3713,2052,3952,0802,080

Share price low (KRW)

3,0701,2351,1532,0802,080

Market cap high (KRW Bn)

127.293.469.860.660.6

Market cap low (KRW Bn)

89.436.033.660.660.6

Valuation Multiples

MultipleCheilbioBasis

Market cap (KRW Bn)

approx. 6.2

KRW 320,000 x 19,419 shares

P/B (x)

approx. 0.20

vs FY2024 equity KRW 31.3bn

EV/Sales (x)

negative

Cash KRW 16.1bn exceeds market cap

Peer reference P/B

Woogene B&G about 0.8x (2025, per company statement to Edaily)

—

Capital Markets

ItemStatus

Analyst consensus

None; no coverage found

Dividend history and policy

No dividends found for FY2021-FY2025; policy not disclosed

Buyback authorisations

Up to 1,940 shares / KRW 2,022.8M (9-20 Feb 2026); 2017 KRW 2.5bn trust

Credit ratings (Moody's/S&P/Fitch)

None; NICE offers a paid credit analysis report (rating not public)

Debt maturity profile

Not publicly disclosed (liabilities KRW 3.9bn total at FY2024)

Trading venue now

No organised exchange market since 23 Feb 2026; any OTC trading arrangements not confirmed

Analyst Conclusions

Management guidance: none published. Consensus: none.

Bull case

  1. Asset backing: at the last traded valuation of about KRW 6.2bn, the equity was priced at roughly 0.2x book and well below the KRW 16.1bn cash balance cited in court, so holders have a large margin of asset cover if value is ever realised or the listing is restored.

  2. Legal momentum: all five criminal complaints have been closed without indictment and the company has won at first instance, the first time KRX has lost on the merits after winning at the injunction stage. A clean FY2025 or FY2026 audit opinion would remove the root cause of the disclaimers.

  3. Operating improvement: operating losses have more than halved in two years (KRW -2.02bn to -0.67bn) with gross margin steady near 23%; modest revenue growth or SG&A trimming could return the business to breakeven within a market growing about 10% a year.

Bear case

  1. Listing may not return: KRX has appealed, and two consecutive disclaimers are an independent formal delisting ground; tighter 2026-2027 KOSDAQ market-cap thresholds would also be hard to meet.

  2. Structural decline: revenue is 63% below its FY2014 peak, the company lost money in each of the last six years, and its margins trail profitable peers by a wide gap, with no disclosed strategy or new products.

  3. Governance overhang: the founder-family dispute is not formally settled, a new 11.6% holder has emerged, investor communication is minimal, and minority shareholders have no exchange liquidity.

Key catalysts and monitorables (next 12 months)

  • Appellate ruling in KRX's appeal against the 10 April 2026 judgement, and any Supreme Court petition.

  • FY2025 audit opinion (if not already clean) and the FY2026 audit opinion due in March 2027.

  • Q3 2026 report (mid-November 2026) and FY2026 results: whether operating income reaches breakeven.

  • Ownership changes: founder-side consolidation versus Lee Kyung-jae group intentions; any EGM requests.

  • Use of cash: buybacks, special distributions, investment or M&A.

  • Any re-listing application, or alternative liquidity arrangements for shareholders.

Analyst verdict. Cheilbio is no longer primarily an operating story; it is a legal and governance situation attached to a small, cash-rich, structurally challenged veterinary manufacturer. On fundamentals, the business has shrunk for a decade, from KRW 39.5bn of revenue in FY2014 to KRW 14.4bn in FY2025, and has not earned an operating profit since at least FY2020. Its gross margin of about 23% sits well below profitable listed peers such as Woogene B&G and Eagle Vet, and the disclosed portfolio suggests a commodity-leaning mix sold heavily through feed mills, where a supplier's reputational damage translates quickly into lost volume, as the 76% collapse in functional additives during FY2023 showed. Against this, the balance sheet is unusually conservative: liabilities of only KRW 3.9bn and roughly KRW 16bn of cash-equivalent assets, which means the company faces no near-term solvency risk and the narrowing of losses since FY2023 is credible.

The decisive variable is the appeal. The first-instance court accepted that the audit disclaimers were driven by allegations later dismissed and that the company's finances were sound, but the exchange retains a strong formal argument from the two consecutive disclaimers, and stricter listing-maintenance rules raise the bar for any return. Even a final win may restore rights more than liquidity.

For a research or counterparty user, Cheilbio should be treated as a going concern with low credit risk but high information risk: interim 2026 figures are not publicly accessible, audit quality has been compromised for three years, and governance remains concentrated in a divided founding family. Equity value, at about 0.2x book on the last traded price, is optionality on a legal outcome rather than on business performance. Confidence in this assessment is limited by the absence of accessible primary filings for 2026 and of any management communication.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenure / datesBackground (as disclosed)

Kang Dong-il (강동일)

Representative director (CEO)

CEO-change filing dated 31 Dec 2024; identified as CEO in Feb 2026 filings coverage

—

Sim Kwang-kyung (심광경)

Founder; chairman; former CEO

Founder 1977; CEO until removal Apr 2023; reinstated Aug 2023

SNU veterinary medicine graduate; age 84 in 2023 (Herald Economy); previously worked at a Korean company before founding

Sim Ui-jeong (심의정)

Largest shareholder; former inside director

Chosen successor in 2016; inside director from Aug 2023 (described as "former" by Apr 2025)

Second daughter of founder

Sim Yun-jeong (심윤정)

Former CEO; 5.23% shareholder

Inside director early 2023; CEO Apr-Aug 2023; removed by EGM

Eldest daughter; family-medicine physician

Kang Ki-hoon (강기훈)

Former president

Party to 2023 complaints

Husband of Sim Yun-jeong (Dealsite)

Sim Seung-gyu (심승규)

Former CEO

CEO around 2015; exited management and shares in 2016; holds 0.01% (2026)

Founder's son

“—” = not publicly disclosed.

Major Shareholders

HolderStake (FnGuide, as of 9-13 Feb 2026)Stake (Saramin/NICE, later snapshot)Notes

Sim Ui-jeong

14.04%19.32%

Largest shareholder

Sim Kwang-kyung

7.11%13.65%

Founder; filed a large-holding report on 24 Feb 2026

Lee Kyung-jae (incl. KJ Corporation)

not listed

11.56%

Reported 8.81% on 10 Feb 2026 and 11.63% (2,258 shares) on 24 Feb 2026, accumulated during liquidation trading (DigitalToday)

Kim Mun-ja

5.29%5.28%

Founder's wife

Sim Yun-jeong

5.23%

not listed

Eldest daughter, adversary in dispute

Treasury shares

5.00%—

970 shares

Jang Jae-wan

0.02%—

Related party

Sim Seung-gyu

0.01%0.01%

Founder's son

Competitive Landscape

Peer Comparison FY2025

MetricCheilbioWoogene B&GEagle Vet

Revenue (KRW Bn)

14.4530.2043.32

Revenue growth YoY (%)

3.914.53.9

Gross margin (%)

23.229.934.1

Operating margin (%)

-4.67.39.8

Net margin (%)

-1.66.29.1

Employees

approx. 48-49

approx. 97-103

108

Listing status

Delisted (litigation pending)

KOSDAQ

KOSDAQ

Company Snapshot

$10.2M

Revenue

42

Employees

1977

Founded

Yongin, South Korea

Headquarters

SWOT Analysis

Strengths

  • Liquidity: cash-equivalent assets of KRW 16.1bn within total assets of KRW 32.9bn, as argued to the court in 2026 (Hankyung).
  • Low leverage: total liabilities of KRW 3.9bn against equity of KRW 31.3bn at FY2024 (DigitalToday), a liabilities-to-equity ratio of 12.5% (derived).
  • Gross margin stabilised at 23.1-23.7% in FY2023-FY2025, up from 15.9% in FY2022 (KIND; JobKorea).
  • Operating losses narrowed two years running: KRW -2.02bn (FY2023) to -1.06bn (FY2024) to -0.67bn (FY2025).
  • Proprietary fermentation heritage since 1990 and 15 patent filings (8 registered) with Inno-Biz certification (Etoday; capa.ai).
  • Diversified product basket across four product lines, with no line above 31% of FY2024 revenue (KIND, derived).

Weaknesses

  • Operating losses in every year FY2020-FY2025 (FnGuide; KIND; JobKorea).
  • Revenue down 63% from the FY2014 peak of KRW 39.53bn to KRW 14.45bn in FY2025 (Edaily; JobKorea).
  • Audit disclaimers on FY2023 and FY2024 annual statements and on H1 2023 and H1 2025 reviews (Herald Economy; Aju News; Money Today).
  • FY2023 revenue restated downward by KRW 2.29bn (KIND), reducing confidence in reported figures.
  • Governance instability: CEO removed and reinstated within five months of 2023; IR officer resigned in 2025 (Herald Economy; Dealsite TV).
  • Gross margin 6.7-10.9 points below listed peers Woogene B&G and Eagle Vet in FY2025 (derived).

Opportunities

  • First-instance court ruling (10 Apr 2026) voiding delisting; if upheld, the company could pursue re-listing review (News1 via Nate).
  • Korean animal-drug market grew 10.5% in 2025 to KRW 1.516trn (KAHPA via Chuksan News).
  • Industry exports rose 15.6% in 2025 to KRW 475.8bn; Cheilbio's export share of sales was 15.65% in FY2024, leaving room to expand.
  • Government target to grow the industry to KRW 4trn by 2035 with export support (Chuksan/Liveinfo).
  • Cash of about KRW 16.1bn could fund product development, capacity or bolt-on deals without external financing.
  • Resolution of all five criminal complaints without indictment (Hankyung) removes the stated basis of past audit disclaimers, potentially enabling a clean opinion.

Threats

  • KRX appeal (filed 23 Apr 2026) could reverse the first-instance ruling (Herald Economy).
  • Industry observers note that two consecutive disclaimers (FY2023, FY2024) are themselves a formal delisting ground, so re-listing may be difficult even with a final court win (Herald Economy).
  • Import share of the domestic market rising every year, from 42.1% (2022) to 45.7% (2025).
  • Profitable domestic peers (Woogene operating margin 7.3%, Eagle Vet 9.8% in FY2025) compete for the same distributors.
  • Unresolved family conflict: the eldest daughter holds 5.23% and pursued appeals through 2025; further litigation possible.
  • Tightening KOSDAQ listing-maintenance rules from 2026, including market-cap thresholds rising to KRW 30bn in 2027 (MTN, Jul 2026), which a company valued around KRW 6bn would not meet on its last traded price.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025FY2024 business report filed; audit disclaimer for the second consecutive yearTriggers formal delisting ground in addition to substantive review
Apr 2025Sim Yun-jeong and co-complainants appeal the non-indictment over the KRW 4.6bn breach-of-trust complaintExtends legal overhang (Dealsite, 24 Apr 2025)
Apr 2025Minority shareholders select a shareholder representative and signal hard-line actionOrganised minority pressure
28 Apr 2025KRX resolves to delist the sharesKey adverse event
29 Apr 2025Company applies for injunction suspending delisting; liquidation trading pausedBuys time
May 2025Company files embezzlement complaint (approx. KRW 62.3M) against a former CEO surnamed SimCounter-litigation within family dispute
11-12 Jun 2025EGM called; record date set; treasury-share disposal decisionCapital actions
16 Jun 2025Suit filed seeking a declaration that the delisting decision is voidMain legal route
17-18 Jul 2025EGM notice; capital-reduction decision; no-par share conversion decisionRestructuring of share capital
21 Jul 2025Disclosure on progress of embezzlement/breach allegationsLegal update
1 Aug 2025EGM approves capital reduction and no-par conversionEnables later consolidation
Aug 2025Disclaimer on H1 2025 review (listed among H1 non-clean opinions by Money Today)Continued audit problem
20 Oct 2025Capital reduction completedRestructuring done
22 Oct 2025Material-event report on filing of a lawsuit (details not disclosed)Further litigation
4 Nov 2025Suwon High Court dismisses applications contesting non-indictment over the KRW 4.6bn complaint; KRW 2.9bn matter already dismissedReduces criminal overhang
Nov 2025Company says its IR officer has resignedWeak investor communication
14 Nov 2025Q3 2025 report filedRoutine
Dec 2025 - Feb 2026All five criminal complaints arising from the control dispute closed without indictment (per company counsel)Basis for court win
8 Jan 2026Court dismisses injunction against delistingDelisting procedure to resume
23 Jan 2026Further court decision disclosure on the injunctionProcedural
2 Feb 2026KRX resumes delisting procedure after company completes change-listing for consolidationLiquidation trading scheduled
5 Feb 2026Buyback decision: up to 1,940 shares, KRW 2.02bn ceilingSupport for holders
9 Feb 2026Liquidation trading starts; 1,500:1 consolidation (29,129,064 to 19,419 shares); price prints up to KRW 890,000 vs theoretical KRW 3.12MHeadline "40,000% surge" was a consolidation artefact
10-24 Feb 2026Lee Kyung-jae group raises stake to 8.81% then 11.63%New significant holder
20 Feb 2026Liquidation trading ends; last price around KRW 320,000Implied value approx. KRW 6.2bn
23 Feb 2026Shares delistedLoss of exchange liquidity
24-25 Feb 2026Founder large-holding report; buyback result reportOwnership changes
23 Mar 2026FY2025 business report filed: revenue KRW 14.45bn, operating loss KRW 0.67bnLosses narrowing
10 Apr 2026Seoul Southern District Court rules delisting void; court finds disclaimer alone insufficient to judge loss of financial soundnessThird such loss for KRX in its history; first after winning at injunction stage
23 Apr 2026KRX appealsOutcome pending
15 May 2026Q1 2026 report filedFigures not found
14 Aug 2026H1 2026 report filedFigures not found

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue fell from KRW 16,900 Mn in FY2021 to KRW 14,447.4 Mn in FY2025.
Cheilbio Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue16,90015,348.69,822.913,907.814,447.4
Revenue as originally reported16,90015,348.612,110.813,907.814,447.4
Cost of sales—12,9047,493.810,689.111,091.5
Gross profit—2,444.62,329.13,218.73,355.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. KIND (Korea Exchange) — Cheilbio FY2024 business report excerpt (kind.krx.co.kr)
  2. Morningstar — Cheil Bio Co Ltd profile (morningstar.com.au)
  3. Simply Wall St — Cheilbio stock report (simplywall.st)
  4. FnGuide — Cheilbio main and investment indicators · comp.fnguide.com
  5. JobKorea/KODATA — Cheilbio financial record (m.jobkorea.co.kr)
  6. Saramin/NICE — Cheilbio financial and shareholder data (saramin.co.kr)
  7. capa.ai — factory registry (capa.ai)
  8. IRGO disclosure list (m.irgo.co.kr)
  9. k5.co.kr disclosure list (k5.co.kr)
  10. Hankyung (Apr 2026) — court ruling (hankyung.com)
  11. Herald Economy (Apr 2026) — KRX appeal · biz.heraldcorp.com · biz.heraldcorp.com
  12. Herald Economy via Daum (Oct 2023) — family dispute history (v.daum.net)
  13. Money Today (Jul 2023) — EGM request (mt.co.kr)
  14. Money Today (Aug 2025) — H1 2025 non-clean opinions (mt.co.kr)
  15. Chosun Biz via Daum (May 2025) (v.daum.net)
  16. Dealsite (Apr 2025) · Dealsite (May 2025)
  17. Dealsite TV (Nov 2025) (news.dealsitetv.com)
  18. Edaily via Nate (Feb 2026) — delisting procedure resumed (news.nate.com)
  19. Chosun Biz via Nate (Feb 2026) — liquidation trading (news.nate.com)
  20. Wikitree (Feb 2026) (wikitree.co.kr)
  21. News1 via Nate (Apr 2026) (m.news.nate.com)
  22. DigitalToday (Feb 2026) — shareholdings, listing date · digitaltoday.co.kr
  23. DigitalToday via Nate (Feb 2026) — buyback (m.news.nate.com)
  24. MTN (Jan 2026; Jul 2026) · news.mtn.co.kr
  25. Metro Seoul (Apr 2024; Apr 2026) · metroseoul.co.kr
  26. Aju News (Nov 2023) (ajunews.com)
  27. Etoday (2015) — company profile · Etoday (2014; 2018) · etoday.co.kr
  28. Edaily historical results · edaily.co.kr · edaily.co.kr · edaily.co.kr
  29. koreascience.kr (2007) — 2006 self-audit award (koreascience.kr)
  30. Woogene B&G (Edaily, Mar 2026; JobKorea) · jobkorea.co.kr
  31. Eagle Vet (JobKorea) (jobkorea.co.kr)
  32. Chuksan News — Korean animal-drug market data · chuksannews.co.kr · chuksannews.co.kr · chuksannews.co.kr · chuksannews.co.kr
  33. Handon News (2024) (pignpork.com)
  34. Liveinfo (2025 industry review) (liveinfo.kr)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.